Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharmaGlobeNewsWire · Oct 13, 2026
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 1, 2026
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual MeetingGlobeNewsWire · Sep 29, 2026
Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha · Sep 9, 2026
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Sep 2, 2026
Dianthus Therapeutics to Participate in Three Investor Conferences During SeptemberGlobeNewsWire · Sep 1, 2026Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$0.85 | -$0.90 | Miss |
| May 5, 2026 | -$1.17 | -$0.85 | Beat |
| Mar 9, 2026 | -$0.98 | -$1.43 | Miss |
| Nov 5, 2025 | -$0.86 | -$0.97 | Miss |
| Aug 7, 2025 | -$0.86 | -$0.88 | Miss |
| May 12, 2025 | -$0.86 | -$0.82 | Beat |